Bronchopulmonary dysplasia (BPD), the chronic lung disease of prematurity, remains a major healthcare burden. Despite great progresses in perinatal medicine over the past decades, no cure for BPD has been found. The complex pathophysiology of the disease further hampers the development of effective treatment strategies, but recent insights into the biology of mesenchymal stem (MSCs) and progenitor cells in lung development and disease have ignited the hope of preventing or even treating BPD. The promising results of pre-clinical studies have lead to the first early phase clinical trials. However, these treatments are experimental and much more needs to be learned about the mechanism of action and manufacturing of MSCs. In this mini review, we briefly summarize the role of resident and exogenous MSCs in the development and treatment of BPD.

中文翻译：

---

间充质基质细胞在支气管肺发育不良的发生和治疗中的作用

支气管肺发育不良 (BPD) 是一种早产儿慢性肺部疾病，仍然是主要的医疗保健负担。尽管在过去的几十年中围产期医学取得了很大进展，但尚未找到治愈 BPD 的方法。该疾病复杂的病理生理学进一步阻碍了有效治疗策略的发展，但最近对间充质干 (MSC) 和祖细胞在肺发育和疾病中的生物学的见解点燃了预防甚至治疗 BPD 的希望。临床前研究的有希望的结果导致了第一个早期临床试验。然而，这些治疗是实验性的，需要更多地了解 MSC 的作用机制和制造。在这篇简短的综述中，我们简要总结了驻留和外源性 MSC 在 BPD 发展和治疗中的作用。